The two companies aim to develop and commercialize a nonavalent HPV vaccine in Russia to help prevent HPV infections and associated diseases, especially cervical cancer
September 5, 2019 - At the East Economic Forum 2019 held in Vladivostok, Russia,
”It is of the utmost importance to make innovative HPV vaccines available to all Russian citizens. This virus provokes genetic mutations leading to cervical cancer, one of the most widely spread oncological diseases in Russia. I strongly believe, that the high-tech product of our partner will help us improve the healthcare system and defeat this dangerous virus once and for all”, said Mr. Alexey Repik.
“Beijing Health Guard remains dedicated to the development of innovative protein-based biologics, specifically vaccines, for the protection against infectious diseases in China and around the globe. We are excited to partner with
About HPV and HPV infections
HPV is a group of more than 200 related viruses, some of which are spread through vaginal, anal, or oral sex. Sexually transmitted HPV types fall into two groups, low risk and high risk. Nearly all sexually active people are infected with HPV almost immediately after they become sexually active. Most HPV infections are self-limiting, while high-risk HPV infections that persist can cause cancers in anatomical sites like cervix, anus, vagina and vulva. HPV vaccines can prevent infection with disease-causing HPV types, and thus protect against many HPV-related cancers and cases of genital warts.
About cervical cancer
Cervical cancer is the second most common gynecological malignancy worldwide, and is diagnosed among ~540,000 women annually, with over 50% of the cohort ending up dead, representing a major global public health concern. Virtually all cervical cancer cases are caused by persistent high risk HPV infection. The Russian healthcare system registered more than 17,500 cases of cervical cancer in 2018. This oncological disease is considered to be the second most common cancer in women under the age of 45 in Russia. According to the data collected by P. A. Hertsen Moscow Oncology Research Center, the number of cervical cancer patients registered in Russia has increased by 30% over the past 10 years.
About the nonavalent HPV vaccine
The production of Beijing Health Guard’s nonavalent HPV vaccine employs patented strategies to express L1 proteins of vaccine HPV types in E. coli as soluble pentamers at low cost and with high efficiency. The derived L1 pentamers can be purified and assemble into highly homogeneous VLPs in vitro without a disassembly-reassembly process. Theoretically, the nonavalent HPV vaccine developed by Beijing Health Guard would afford protection against ~90% of cervical cancer cases and more than 90% of genital warts. Currently, Phase I study has been initiated for the nonavalent HPV vaccine in China.
About Beijing Health Guard
Beijing Health Guard Biotechnology Inc., a clinical-stage biopharmaceutical company, is committed to the discovery, development and commercialization of innovative biologics for the prevention of infectious diseases. Beijing Health Guard’s structure-guided vaccine design platform has generated two investigational HPV vaccines, i.e. a trivalent and a nonavalent HPV vaccine, both of which are currently in clinical trials (Phase II concluded for the trivalent, Phase I underway for the nonavalent). Other ongoing research efforts include the development of a 15-valent HPV vaccine, a quadrivalent HFMD vaccine, a polyvalent norovirus vaccine, and a therapeutic HPV vaccine. Beijing Health Guard is certified by Beijing Municipal Science & Technology Commission as a National High-Tech Enterprise.